What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

View Full Paper

Ask AI

Bookmark

Authors

Real-world analysis finds accelerated glofitamab dosing leads to lower efficacy outcomes in high-risk R/R DLBCL, indicating need for safer protocols.

Accelerated glofitamab dosing led to a 42% overall response rate in high-risk patients.
Key adverse events included high rates of cytokine release syndrome, affecting 61% of patients.
Analysis of dosing revealed the necessity of obinutuzumab and dexamethasone for managing complications.
Study outcomes reinforce the importance of tailored treatment approaches for high-risk R/R DLBCL patients.

Biwei Cao (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Real-world analysis finds accelerated glofitamab dosing leads to lower efficacy outcomes in high-risk R/R DLBCL, indicating need for safer protocols.

Accelerated glofitamab dosing led to a 42% overall response rate in high-risk patients.
Key adverse events included high rates of cytokine release syndrome, affecting 61% of patients.
Analysis of dosing revealed the necessity of obinutuzumab and dexamethasone for managing complications.
Study outcomes reinforce the importance of tailored treatment approaches for high-risk R/R DLBCL patients.

Biwei Cao (2025) studied this question.

View Full Paper

Ask AI

Bookmark